AroCell AB (publ) Interim Report January 1st to December 31st, 2021 – marketscreener.com

A word from the CEO
”2021 has been an exceptional and important year for AroCell, which has been characterized by major changes and a high work pace. The acquisition of IDL Biotech was a significant step forward for AroCell and now the AroCell Group has a strong foundation that creates a good foundation for implementing our strategy.
To be able to continue the commercialization of our existing products, and to develop and apply for regulatory approval for new products and markets, we have completed a new issue of 86 MSEK. Thanks to the support we received from our shareholders in the now completed share issue, we have everything in place to implement our business plan.
It’s reassuring that despite the restrictions inflicted by the COVID 19 pandemic, we see a strong recovery and growth in the oncology segment, we also saw an all-time high in sales in Germany in 2021. Now that COVID restrictions are loosening and more markets are opening up, there is good hope for continued rapid growth in our oncology segment. During the pandemic, AroCell has systematically reached out to new markets for our bacteriology product TUBEX® TF, which we hope to see results of soon. In parallel with this, planning for future clinical studies that will form the basis for several approvals of our products on new markets are ongoing.”Anders Hultman, CEO
Reporting period October 1stDecember 31st
Reporting period January 1stDecember 31st
Please note that IDL Biotech is only included in the second half of the year.
*Net sales for the period including IDL Biotech correspond to 23,032 (21,832) KSEK.
Events during the reporting period October 1stDecember 31st
Events after the reporting period
Interim report January 1stDecember 31st, 2021 (available in Swedish only) (Link)
ContactsAnders Hultman, CEO
Phone: +46(0)18 50 30 20
E-mail: anders.hultman@arocell.com
About AroCell
AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare and established in various markets. In oncology, AroCell uses various biomarkers, TK1 and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell‘s product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com
This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-02-24 08:00 CET.
Attachments
Delårsrapport 2021 Q4
PM Q4 2021 ENG
© Modular Finance, source Nordic Press Releases

source

By Kwetu Buzz

Leave a Reply

Your email address will not be published.